Latest Production Development News

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Connexion Mobility Limited reported a robust 15% revenue increase and a 43% jump in profit after tax for the half-year ended December 2024, underscoring its growing foothold in automotive SaaS solutions while continuing to invest in future growth.

Elixinol Wellness delivered a standout Q4 FY24 performance with a 71% jump in cash receipts and a 64% rise in revenue, driven by key acquisitions and operational efficiencies. The company edges closer to EBITDA break-even, setting the stage for growth in 2025.

BluGlass Limited has secured over A$4 million in new contracts and filed three US patents for high-power tunable GaN lasers, reinforcing its leadership in visible laser technology and expanding its footprint in strategic photonics markets.

Nanollose Limited has secured $2.1 million in strategic funding to accelerate the commercialisation of its sustainable fibres and soilless growth technologies, marking a pivotal shift from R&D to market-ready products.

One Click Group Limited reported a 42% increase in registered users and a 26% rise in revenue to $4.9 million in Q4 2024, while preparing to launch its new superannuation product in 2025.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

xReality Group Limited has reported its strongest quarter yet, with cash receipts soaring 87% year-on-year to $5.2 million, driven by robust growth in its Operator XR enterprise software and entertainment divisions.

Beonic's Q2 FY2025 results reveal steady recurring revenue growth and a significant gross margin improvement, underpinning its path to cashflow breakeven. Strategic contract wins and leadership appointments position the company for accelerated IoT adoption.

ImpediMed Limited has reported record quarterly revenue and cash receipts for Q2 FY25, alongside significant growth in reimbursement coverage and a robust sales pipeline, signaling strong momentum in its digital health platform business.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.